Dr. Reddy’s: The generic effect - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr. Reddy’s: The generic effect

Jan 9, 2002

Dr. Reddy’s is expected to report another spectacular quarterly performance for 3QFY02. While sales (incl. milestone receipts) is expected to record a jump of more than 85%, net profit is likely to explode with a 331% rise. Operating margins are likely to record a quantum jump, mainly due to a larger contribution from high margin generic exports.The spurt in export margins is expected on the back of exports of generic fluoxetine to the US markets. It may be recalled that Dr. Reddy’s received six month marketing exclusivity for this drug (Para IV) in August’01. The company had recorded sales of Rs 1,639 m in the last quarter from sales of fluoxetine with very high operating margins. We expect fluoxetine sales to record revenues of around Rs 950 m in 3QFY02 due to earlier stock build up.

Dr. Reddy’s: High Voltage Performance
(Rs m)3QFY013QFY02E% change
Sales 2,144 3,977 85.5%
Operating Profit (EBDIT) 457 1,556 240.9%
Operating Profit Margin (%)21.3%39.1% 
Profit after Tax/(Loss) 320 1,377 331.0%
Net profit margin (%)14.9%34.6% 
Fully Diluted Earnings per share*17.374.4 

Dr. Reddy’s is also expected to receive a milestone payment of US $ 2.5 m from Novo Nordisk. This milestone receipt has been triggered by DRF- 2725 entering Phase III in Nov’01. Excluding sales of fluoxetine and receipt of milestone payments, sales growth is expected to be 36%. This is also because of the merger effect with American remedies.

At the current market price of Rs 970, the stock trades at a P/e of 15x its expected earnings for FY02. However, one should also keep in mind that supernormal profits are expected to vanish from 4QFY02, as the company loses marketing exclusivity over fluoxetine. The spurt in operating margins was mainly because a six-month Para IV approval ensures high profit margins, due to absence of generic competition. Next Para IV application for the company is atleast 24 months away.

Armed with huge cash reserves, an acquisition of a marketing company in the US may be in the offing. On the R&D front, DRF – 2725, the anti-diabetes molecule licensed to Novo Nordisk is at advanced trial stage before entering the commercialization stage. This could trigger huge royalty for the company (though disappointment on this front even at this stage cannot be ruled out.)

Comparative Valuation
ParticularsCMPP/eMkt.Cap
 (Rs.)2002E2003E(In Mn.)
Ranbaxy72624.424.584,143
Cipla118028.422.170,800
Dr.Reddy's97014.524.774,108

Equitymaster requests your view! Post a comment on "Dr. Reddy’s: The generic effect ". Click here!

  

More Views on News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

6 Penny Stocks that Rallied 1,000%+ in One Year (Views On News)

Dec 6, 2021

These penny stocks shed their penny status by surging 1,000% or more in the last one year.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Dec 9, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - MESCO PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS